Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007

Alan Ashworth, Frances Balkwill, Robert C. Bast, Jonathan S. Berek, Allyson Kaye, Jeffrey A. Boyd, Gordon Mills, John N. Weinstein, Katie Woolley, Paul Workman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Advances in surgery and chemotherapy have improved the 5-year survival for patients with epithelial ovarian cancer, but have not impacted on the ultimate rate of cure in a disease that is diagnosed in late stage and that recurs in the majority of patients. "Omic" technologies promise to define genetically driven aberrant signaling pathways in malignant cells, provided that bioinformatic expertise can be focused on a cancer that is neither common nor rare. Molecular therapeutics must be linked to molecular diagnostics to permit individualized therapy. Not only epithelial cancer cells but also stroma, vasculature and the immune response must be targeted. Closer collaboration between academic institutions, biotech and pharma will be required to facilitate this process and to interest the private sector in an orphan disease. New preclinical models may permit more efficient development of drugs and siRNA that can target dormant drug resistant stem cells. Strategies must be developed to deal with the heterogeneity of different grades and histotypes. Identification of women at increased risk will facilitate prevention and early detection in subsets of patients. BRCA1/2 might be sequenced in all ovarian cancer patients to identify new kindreds. Epidemiologic algorithms are being developed and validated. Awareness must be raised that oral contraceptives can reduce risk of developing ovarian cancer by 50%. Early detection is likely to require panels of complementary biomarkers, analyzed by sophisticated statistical techniques, to improve sensitivity while maintaining extremely high specificity. As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors.

Original languageEnglish (US)
Pages (from-to)652-657
Number of pages6
JournalGynecologic Oncology
Volume108
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Lakes
Ovarian Neoplasms
Research
Private Sector
Molecular Pathology
Oral Contraceptives
Rare Diseases
Computational Biology
Pharmaceutical Preparations
Small Interfering RNA
Survivors
Neoplasms
Chronic Disease
Stem Cells
Biomarkers
Epithelial Cells
Technology
Drug Therapy
Survival
Therapeutics

Keywords

  • Drug development
  • Early detection
  • Genomics
  • Ovarian cancer
  • Risk

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. / Ashworth, Alan; Balkwill, Frances; Bast, Robert C.; Berek, Jonathan S.; Kaye, Allyson; Boyd, Jeffrey A.; Mills, Gordon; Weinstein, John N.; Woolley, Katie; Workman, Paul.

In: Gynecologic Oncology, Vol. 108, 01.03.2008, p. 652-657.

Research output: Contribution to journalArticle

Ashworth, Alan ; Balkwill, Frances ; Bast, Robert C. ; Berek, Jonathan S. ; Kaye, Allyson ; Boyd, Jeffrey A. ; Mills, Gordon ; Weinstein, John N. ; Woolley, Katie ; Workman, Paul. / Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. In: Gynecologic Oncology. 2008 ; Vol. 108. pp. 652-657.
@article{f372f725dadb47d5b0e4b515bed86ea1,
title = "Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007",
abstract = "Advances in surgery and chemotherapy have improved the 5-year survival for patients with epithelial ovarian cancer, but have not impacted on the ultimate rate of cure in a disease that is diagnosed in late stage and that recurs in the majority of patients. {"}Omic{"} technologies promise to define genetically driven aberrant signaling pathways in malignant cells, provided that bioinformatic expertise can be focused on a cancer that is neither common nor rare. Molecular therapeutics must be linked to molecular diagnostics to permit individualized therapy. Not only epithelial cancer cells but also stroma, vasculature and the immune response must be targeted. Closer collaboration between academic institutions, biotech and pharma will be required to facilitate this process and to interest the private sector in an orphan disease. New preclinical models may permit more efficient development of drugs and siRNA that can target dormant drug resistant stem cells. Strategies must be developed to deal with the heterogeneity of different grades and histotypes. Identification of women at increased risk will facilitate prevention and early detection in subsets of patients. BRCA1/2 might be sequenced in all ovarian cancer patients to identify new kindreds. Epidemiologic algorithms are being developed and validated. Awareness must be raised that oral contraceptives can reduce risk of developing ovarian cancer by 50{\%}. Early detection is likely to require panels of complementary biomarkers, analyzed by sophisticated statistical techniques, to improve sensitivity while maintaining extremely high specificity. As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors.",
keywords = "Drug development, Early detection, Genomics, Ovarian cancer, Risk",
author = "Alan Ashworth and Frances Balkwill and Bast, {Robert C.} and Berek, {Jonathan S.} and Allyson Kaye and Boyd, {Jeffrey A.} and Gordon Mills and Weinstein, {John N.} and Katie Woolley and Paul Workman",
year = "2008",
month = "3",
day = "1",
doi = "10.1016/j.ygyno.2007.11.014",
language = "English (US)",
volume = "108",
pages = "652--657",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007

AU - Ashworth, Alan

AU - Balkwill, Frances

AU - Bast, Robert C.

AU - Berek, Jonathan S.

AU - Kaye, Allyson

AU - Boyd, Jeffrey A.

AU - Mills, Gordon

AU - Weinstein, John N.

AU - Woolley, Katie

AU - Workman, Paul

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Advances in surgery and chemotherapy have improved the 5-year survival for patients with epithelial ovarian cancer, but have not impacted on the ultimate rate of cure in a disease that is diagnosed in late stage and that recurs in the majority of patients. "Omic" technologies promise to define genetically driven aberrant signaling pathways in malignant cells, provided that bioinformatic expertise can be focused on a cancer that is neither common nor rare. Molecular therapeutics must be linked to molecular diagnostics to permit individualized therapy. Not only epithelial cancer cells but also stroma, vasculature and the immune response must be targeted. Closer collaboration between academic institutions, biotech and pharma will be required to facilitate this process and to interest the private sector in an orphan disease. New preclinical models may permit more efficient development of drugs and siRNA that can target dormant drug resistant stem cells. Strategies must be developed to deal with the heterogeneity of different grades and histotypes. Identification of women at increased risk will facilitate prevention and early detection in subsets of patients. BRCA1/2 might be sequenced in all ovarian cancer patients to identify new kindreds. Epidemiologic algorithms are being developed and validated. Awareness must be raised that oral contraceptives can reduce risk of developing ovarian cancer by 50%. Early detection is likely to require panels of complementary biomarkers, analyzed by sophisticated statistical techniques, to improve sensitivity while maintaining extremely high specificity. As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors.

AB - Advances in surgery and chemotherapy have improved the 5-year survival for patients with epithelial ovarian cancer, but have not impacted on the ultimate rate of cure in a disease that is diagnosed in late stage and that recurs in the majority of patients. "Omic" technologies promise to define genetically driven aberrant signaling pathways in malignant cells, provided that bioinformatic expertise can be focused on a cancer that is neither common nor rare. Molecular therapeutics must be linked to molecular diagnostics to permit individualized therapy. Not only epithelial cancer cells but also stroma, vasculature and the immune response must be targeted. Closer collaboration between academic institutions, biotech and pharma will be required to facilitate this process and to interest the private sector in an orphan disease. New preclinical models may permit more efficient development of drugs and siRNA that can target dormant drug resistant stem cells. Strategies must be developed to deal with the heterogeneity of different grades and histotypes. Identification of women at increased risk will facilitate prevention and early detection in subsets of patients. BRCA1/2 might be sequenced in all ovarian cancer patients to identify new kindreds. Epidemiologic algorithms are being developed and validated. Awareness must be raised that oral contraceptives can reduce risk of developing ovarian cancer by 50%. Early detection is likely to require panels of complementary biomarkers, analyzed by sophisticated statistical techniques, to improve sensitivity while maintaining extremely high specificity. As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors.

KW - Drug development

KW - Early detection

KW - Genomics

KW - Ovarian cancer

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=39249085679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39249085679&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.11.014

DO - 10.1016/j.ygyno.2007.11.014

M3 - Article

C2 - 18096210

AN - SCOPUS:39249085679

VL - 108

SP - 652

EP - 657

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -